Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.
2.

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L.

Vasc Med. 2015 Oct;20(5):465-78. doi: 10.1177/1358863X15597877. Epub 2015 Aug 12. Review.

PMID:
26268268
3.

An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee.

Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L.

Catheter Cardiovasc Interv. 2015 Oct;86(4):611-25. doi: 10.1002/ccd.26122. Epub 2015 Aug 10. Review.

PMID:
26256456
4.

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L.

J Endovasc Ther. 2015 Oct;22(5):663-77. doi: 10.1177/1526602815592206. Epub 2015 Aug 3. Review.

PMID:
26239796
5.

Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.

Doehner W, Erdmann E, Cairns R, Clark AL, Dormandy JA, Ferrannini E, Anker SD.

Int J Cardiol. 2012 Dec 15;162(1):20-6. doi: 10.1016/j.ijcard.2011.09.039. Epub 2011 Oct 29.

PMID:
22037349
6.

Reprinted article "The fate of the claudicant--a prospective study of 1969 claudicants".

Dormandy JA, Murray GD.

Eur J Vasc Endovasc Surg. 2011 Sep;42 Suppl 1:S4-6. doi: 10.1016/j.ejvs.2011.06.014.

7.

High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive.

Ferrannini E, Betteridge DJ, Dormandy JA, Charbonnel B, Wilcox RG, Spanheimer R, Erdmann E, Defronzo RA, Laakso M.

Diabetes Obes Metab. 2011 Aug;13(8):759-64. doi: 10.1111/j.1463-1326.2011.01404.x.

PMID:
21457426
8.

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.

Belch JJ, Dormandy J; CASPAR Writing Committee, Biasi GM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepäntalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A.

J Vasc Surg. 2010 Oct;52(4):825-33, 833.e1-2. doi: 10.1016/j.jvs.2010.04.027. Epub 2010 Aug 1. Erratum in: J Vasc Surg. 2011 Feb;53(2):564. Biasi, B M [corrected to Biasi, G M].

9.

The next 10 years in the management of peripheral artery disease: perspectives from the 'PAD 2009' Conference.

Norgren L, Hiatt WR, Dormandy JA, Hirsch AT, Jaff MR, Diehm C, Baumgartner I, Belch JJ.

Eur J Vasc Endovasc Surg. 2010 Sep;40(3):375-80. doi: 10.1016/j.ejvs.2010.05.005. Epub 2010 Jun 15.

10.

Mycobacterium tuberculosis complex differentiation by genomic deletion patterns with multiplex polymerase chain reaction and melting analysis.

Pounder JI, Anderson CM, Voelkerding KV, Salfinger M, Dormandy J, Somoskovi A, Heifets L, Graham JJ, Storts DR, Petti CA.

Diagn Microbiol Infect Dis. 2010 May;67(1):101-5. doi: 10.1016/j.diagmicrobio.2009.12.014. Epub 2010 Mar 12.

PMID:
20227227
11.

Risk of thiazolidinedione-associated fracture should be appropriately assessed.

van Troostenburg de Bruyn AR, Dormandy J.

Arch Intern Med. 2010 Jan 25;170(2):209-10. doi: 10.1001/archinternmed.2009.487. No abstract available.

PMID:
20101019
12.

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.

Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators.

Drug Saf. 2009;32(3):187-202. doi: 10.2165/00002018-200932030-00002. Review.

PMID:
19338377
13.

"Mycobacterium canettii" isolated from a human immunodeficiency virus-positive patient: first case recognized in the United States.

Somoskovi A, Dormandy J, Mayrer AR, Carter M, Hooper N, Salfinger M.

J Clin Microbiol. 2009 Jan;47(1):255-7. doi: 10.1128/JCM.01268-08. Epub 2008 Nov 19.

14.

Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11).

Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; PROactive investigators.

Atherosclerosis. 2009 Jan;202(1):272-81. doi: 10.1016/j.atherosclerosis.2008.03.002. Epub 2008 Mar 18.

PMID:
18538774
15.

Direct comparison of the genotype MTBC and genomic deletion assays in terms of ability to distinguish between members of the Mycobacterium tuberculosis complex in clinical isolates and in clinical specimens.

Somoskovi A, Dormandy J, Rivenburg J, Pedrosa M, McBride M, Salfinger M.

J Clin Microbiol. 2008 May;46(5):1854-7. doi: 10.1128/JCM.00105-07. Epub 2008 Mar 19.

16.

PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B.

Vasc Health Risk Manag. 2007;3(4):355-70. Review.

17.

Mediastinal mass mimicking a tumor in a patient with bladder cancer after Bacillus Calmette-Guerin treatment.

Somoskovi A, Carlyn C, Dormandy J, Salfinger M.

Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):937-40.

PMID:
17899227
18.

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA; PROactive Investigators.

Diabetes Care. 2007 Nov;30(11):2773-8. Epub 2007 Jul 31.

PMID:
17666462
19.

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.

PMID:
17593245
20.

Inter-society consensus for the management of peripheral arterial disease.

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Rutherford RB; TASC II Working Group.

Int Angiol. 2007 Jun;26(2):81-157. Review. No abstract available.

PMID:
17489079
21.

Chronic critical ischemia of the legs.

Dormandy J, Becker F.

Ann Cardiol Angeiol (Paris). 2007 Apr;56(2):61-2. No abstract available.

PMID:
17484088
22.

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators.

J Am Coll Cardiol. 2007 May 1;49(17):1772-80. Epub 2007 Apr 16.

23.

Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes.

Nehler MR, Brass EP, Anthony R, Dormandy J, Jiao J, McNamara TO, Hiatt WR; Circulase investigators.

J Vasc Surg. 2007 May;45(5):953-60; discussion 960-1. Epub 2007 Mar 9.

25.

Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).

Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators.

Stroke. 2007 Mar;38(3):865-73. Epub 2007 Feb 8.

PMID:
17290029
26.

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group.

J Vasc Surg. 2007 Jan;45 Suppl S:S5-67. No abstract available.

27.

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K.

Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75. Epub 2006 Nov 29. No abstract available.

29.
30.

[Positioning of PROactive and its clinical application in Japan--a new direction in diabetes care discussed by diabetology and circulatory disease specialists: discussion].

Kawamori R, Kadowaki T, Daida H, Takeda N, Dormandy J.

Nihon Rinsho. 2006 Mar;64(3):581-7. Japanese. No abstract available.

PMID:
16732624
31.

Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.

Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, McNamara T, Nehler M; Circulase investigators.

J Vasc Surg. 2006 Apr;43(4):752-9.

32.

The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease.

Vig S, Chitolie A, Bevan D, Dormandy J, Thompson MM, Halliday A.

Br J Surg. 2006 May;93(5):577-81.

PMID:
16607693
33.

Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4.

Matyas L, Schulte KL, Dormandy JA, Norgren L, Sowade O, Grötzbach G, Palmer-Kazen U, Rubanyi GM, Wahlberg E.

Hum Gene Ther. 2005 Oct;16(10):1202-11.

PMID:
16218781
34.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators.

Lancet. 2005 Oct 8;366(9493):1279-89.

35.

Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol.

Parsons LM, Salfinger M, Clobridge A, Dormandy J, Mirabello L, Polletta VL, Sanic A, Sinyavskiy O, Larsen SC, Driscoll J, Zickas G, Taber HW.

Antimicrob Agents Chemother. 2005 Jun;49(6):2218-25.

36.

Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial.

Powell RJ, Dormandy J, Simons M, Morishita R, Annex BH.

Vasc Med. 2004 May;9(3):193-8.

PMID:
15675184
37.

Prevalence and risk of thrombophilia defects in vascular patients.

Vig S, Chitolie A, Sleight S, Bevan D, Dormandy J, Thompson MM, Halliday A.

Eur J Vasc Endovasc Surg. 2004 Aug;28(2):124-31. Review.

38.
39.

A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia.

Plouin PF, Clement DL, Boccalon H, Dormandy J, Durand-Zaleski I, Fowkes G, Norgren L, Brown T.

Int Angiol. 2003 Dec;22(4):333-9. Review.

40.

Thromboelastography: a reliable test?

Vig S, Chitolie A, Bevan DH, Halliday A, Dormandy J.

Blood Coagul Fibrinolysis. 2001 Oct;12(7):555-61.

PMID:
11685044
41.

Study of temporal and perfusion physiology of skin capillaries in the dorsum of the foot.

Lamah M, Mortimer PS, Dormandy JA.

J Vasc Res. 2001 Jan-Feb;38(1):59-63.

PMID:
11173995
42.

Thromboelastography.

Vig S, Chitolie A, Bevan D, Halliday A, Dormandy JA.

Hematology. 2001;6(3):205-13. doi: 10.1080/10245332.2001.11746573.

PMID:
27420127
43.

Interpretation of quantitative measurement of skin capillaries using native in vivo microscopy.

Lamah M, Mortimer PS, Dormandy JA.

Microvasc Res. 2000 Sep;60(2):189-92. No abstract available.

PMID:
10964594
44.

A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis).

Clement DL, Boccalon H, Dormandy J, Durand-Zaleski I, Fowkes G, Brown T.

Int Angiol. 2000 Jun;19(2):97-125. Review.

PMID:
10905794
45.

Major amputations: clinical patterns and predictors.

Dormandy J, Heeck L, Vig S.

Semin Vasc Surg. 1999 Jun;12(2):154-61. Review.

PMID:
10777243
46.

Acute limb ischemia.

Dormandy J, Heeck L, Vig S.

Semin Vasc Surg. 1999 Jun;12(2):148-53. Review.

PMID:
10777242
47.

The fate of patients with critical leg ischemia.

Dormandy J, Heeck L, Vig S.

Semin Vasc Surg. 1999 Jun;12(2):142-7. Review.

PMID:
10777241
48.

Predicting which patients will develop chronic critical leg ischemia.

Dormandy J, Heeck L, Vig S.

Semin Vasc Surg. 1999 Jun;12(2):138-41. Review.

PMID:
10777240
49.

The natural history of claudication: risk to life and limb.

Dormandy J, Heeck L, Vig S.

Semin Vasc Surg. 1999 Jun;12(2):123-37. Review.

PMID:
10777239
50.

Supplemental Content

Loading ...
Support Center